Generic name: ELVITEGRAVIR 85mg
Dosage form: tablet, film coated
Medically reviewed on July 31, 2017.
VITEKTA must be administered once daily with food in combination with a protease inhibitor coadministered with ritonavir and another antiretroviral drug. The protease inhibitor and ritonavir dosing regimens presented in Table 1 are the recommended regimens for use with VITEKTA. For additional dosing instructions for these protease inhibitors and other concomitant antiretroviral drugs, refer to their respective prescribing information.
|Dosage of VITEKTA||Dosage of Concomitant Protease Inhibitor||Dosage of Concomitant Ritonavir|
|85 mg orally once daily||Atazanavir 300 mg orally once daily||100 mg orally once daily|
|Lopinavir 400 mg orally twice daily||100 mg orally twice daily|
|150 mg orally once daily||Darunavir 600 mg orally twice daily||100 mg orally twice daily|
|Fosamprenavir 700 mg orally twice daily||100 mg orally twice daily|
|Tipranavir 500 mg orally twice daily||200 mg orally twice daily|
Treatment history and, when available, resistance testing should guide the use of VITEKTA-containing regimens.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Vitekta (elvitegravir)
- Vitekta Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- 0 Reviews
- Drug class: integrase strand transfer inhibitor